Blood Collection From People With Ovarian Cancer
NCT02063464 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85
Last updated 2023-05-24
Summary
Background:
* Monocytes are a type of white blood cell found in human blood. They help the immune system. Researchers have found that monocytes taken from the blood of healthy people can kill tumor cells. Now they want to know if monocytes taken from the blood of people with ovarian cancer can kill tumor cells.
* In addition, native host anti-tumor cell mediated immune mechanisms may play a role in clinical outcome of epithelial ovarian cancer; data indicate that the presence of intra-tumoral CD3+ T-cells was shown to prognosticate improved outcome in advanced ovarian cancer. Furthermore, non-cellular components in the blood, such as exosomes, may influence outcome.
Objective:
\- To see if monocytes taken from the blood of people with ovarian cancer can kill tumor cells.
Eligibility:
\- Women 18 years and older with ovarian cancer.
Design:
* Participants will be screened with:
* Medical history and physical exam.
* Blood tests.
* CT scan of the chest, abdomen, and pelvis and/or an MRI. For these scans, they will lie in a machine that takes pictures of their body.
* A small amount of blood (two tubes) will be collected by needle during one visit.
Conditions
- Ovarian Cancer
- Cancer of the Ovary
- Ovarian Neoplasms
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Christina M Annunziata, M.D. · National Cancer Institute (NCI)
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-03-10
- Primary Completion
- 2016-03-14
- Completion
- 2016-11-16
Countries
- United States
Study Locations
More Related Trials
-
Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer
NCT03922776 ·Status: TERMINATED ·Phase: NA
-
Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer
NCT01096394 ·Status: COMPLETED
-
Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00004064 ·Status: UNKNOWN ·Phase: PHASE2
-
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
NCT00562640 ·Status: COMPLETED ·Phase: PHASE1
-
Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer
NCT04072263 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
NCT05446298 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
NCT01219777 ·Status: COMPLETED ·Phase: PHASE1
-
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
NCT01506856 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
NCT00043472 ·Status: COMPLETED
-
Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer
NCT00002928 ·Status: COMPLETED ·Phase: PHASE2
-
Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer
NCT03606486 ·Status: TERMINATED ·Phase: NA
-
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00373217 ·Status: TERMINATED ·Phase: PHASE2
-
Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
NCT00003634 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00003944 ·Status: COMPLETED ·Phase: PHASE2
-
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT02948426 ·Status: TERMINATED ·Phase: PHASE1
-
Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer
NCT04417192 ·Status: COMPLETED ·Phase: PHASE2
-
Risk of Ovarian Cancer in Patients With a Pelvic Mass
NCT00315692 ·Status: COMPLETED
-
Neoadjuvant Therapy for Ovarian Cancer
NCT01146795 ·Status: COMPLETED ·Phase: PHASE2
-
S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer
NCT00008138 ·Status: COMPLETED ·Phase: PHASE2
-
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
NCT05236686 ·Status: RECRUITING ·Phase: NA
-
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
NCT01248962 ·Status: COMPLETED ·Phase: PHASE2
-
CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00096239 ·Status: COMPLETED ·Phase: PHASE2
-
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
NCT04794322 ·Status: RECRUITING
-
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT01295489 ·Status: COMPLETED
-
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
NCT04611126 ·Status: TERMINATED ·Phase: PHASE1/PHASE2